Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic, Translational & Therapy: Radiopharmaceutical Therapy

Peptide receptor radiotherapy (PRRT) as a potential tool of neoadjuvant therapy in patients with inoperable neuroendocrine tumors (NETs)

Anna Sowa-Staszczak, Dorota Pach, Agnieszka Stefanska, Monika Tomaszuk, Renata Mikolajczak, Dariusz Pawlak, Malgorzata Trofimiuk, Robert Chrzan and Alicja Hubalewska-Dydejczyk
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 1743;
Anna Sowa-Staszczak
1Nuclear Medicine Unit, Endocrinology Department, Jagiellonian University, Medical College, Krakow, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dorota Pach
1Nuclear Medicine Unit, Endocrinology Department, Jagiellonian University, Medical College, Krakow, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Agnieszka Stefanska
1Nuclear Medicine Unit, Endocrinology Department, Jagiellonian University, Medical College, Krakow, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monika Tomaszuk
1Nuclear Medicine Unit, Endocrinology Department, Jagiellonian University, Medical College, Krakow, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renata Mikolajczak
2Research and Development, IAE Radioisotope Centre POLATOM, Otwock-Swierk, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dariusz Pawlak
2Research and Development, IAE Radioisotope Centre POLATOM, Otwock-Swierk, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malgorzata Trofimiuk
1Nuclear Medicine Unit, Endocrinology Department, Jagiellonian University, Medical College, Krakow, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Chrzan
3Department of Radiology, Jagiellonian University, Medical College, Krakow, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alicja Hubalewska-Dydejczyk
1Nuclear Medicine Unit, Endocrinology Department, Jagiellonian University, Medical College, Krakow, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1743

Objectives Surgical eradication is the main aim in the treatment of NETs, which becomes impossible in the case of large tumors or infiltration into other tissues and/or important blood vessels. Neoadjuvant therapy might be helpful in decreasing neuroendocrine tumor’ size also.

Methods Within the group of 47 patients treated with PRRT, 6 patients were chosen with large, inoperable tumors, for whom enabling of complete surgical excision of the lesions might be the prospect for a cure. There were 5 patients with foregut tumors and 1 with midgut tumor). Every patient received a dose of 7.4 GBq/m2 90Y-DOTA TATE in 4-5 cycles every 6-9 weeks. The mean dose was 13.6 GBq (min 11.1 GBq, max 14.8 GBq). Response to the therapy was assessed according to RECIST criteria.

Results After the treatment, mean tumor size decreased to 6.9 cm with SD 2 cm (min 3.1 cm, max 9.6 cm). According to RECIST criteria, stabilization of the disease was observed in 4, partial responses in 2 patients. In two patients, reduction of the tumor size enabled surgical intervention.

Conclusions 1. PRRT might be considered a neoadjuvant therapy in primary inoperable neuroendocrine tumors. 2. According to RECIST criteria stabilization of the disease was observed in the majority of patients. 3. We suggest that not only tumor’ diameter changes, but also tumor’ volume and contrast enhancement changes in CT should be taken into consideration in assessment of the response to the therapy

Back to top

In this issue

Journal of Nuclear Medicine
Vol. 52, Issue supplement 1
May 2011
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Peptide receptor radiotherapy (PRRT) as a potential tool of neoadjuvant therapy in patients with inoperable neuroendocrine tumors (NETs)
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Peptide receptor radiotherapy (PRRT) as a potential tool of neoadjuvant therapy in patients with inoperable neuroendocrine tumors (NETs)
Anna Sowa-Staszczak, Dorota Pach, Agnieszka Stefanska, Monika Tomaszuk, Renata Mikolajczak, Dariusz Pawlak, Malgorzata Trofimiuk, Robert Chrzan, Alicja Hubalewska-Dydejczyk
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 1743;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Peptide receptor radiotherapy (PRRT) as a potential tool of neoadjuvant therapy in patients with inoperable neuroendocrine tumors (NETs)
Anna Sowa-Staszczak, Dorota Pach, Agnieszka Stefanska, Monika Tomaszuk, Renata Mikolajczak, Dariusz Pawlak, Malgorzata Trofimiuk, Robert Chrzan, Alicja Hubalewska-Dydejczyk
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 1743;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic, Translational & Therapy: Radiopharmaceutical Therapy

  • Characterization of 177Lu-Affibody-HSA bioconjugate for radionuclide therapy of EGFR-expressing head and neck carcinomas
  • Low-dose hyper-radiosensitivity model for 131I radioimmunotherapy of non-Hodgkin’s lymphoma
  • Monitoring the correlation between I-uptake and apoptosis using Apoptosis-targeting peptide-1 (ApoPep-1)
Show more Oncology: Basic, Translational & Therapy: Radiopharmaceutical Therapy

Radiopharmaceutical Therapy Posters

  • The study of iodide uptake change by transfection of a recombinant eukaryotic expression plasmid pcDNA3.1/hTSHR cDNA in FTC-133 cell lines
  • Animal study of an intelligent 188Re-Doxorubicin-Hydrogel system to treat hepatic tumor
  • 177Lu-EDTMP - A bone pain palliating agent: Biodistribution and skeletal uptake in osseous metastatic patients
Show more Radiopharmaceutical Therapy Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire